Get in touch to find out more

Thank you for your submission!

Oops! Something went wrong while submitting the form.

January 10, 2023

Oxford Cancer Analytics Raises $3.7M Led by Eka Ventures to Revolutionize Liquid Biopsy and Early Cancer Detection

Oxford Cancer Analytics is pioneering a new generation of blood based liquid biopsy tests for early cancer detection, and has announced the completion of an additional seed financing round, led by Eka Ventures, with participation from LifeArc, MegaRobo Technologies, Oxford Technology Management, and value-add individual investors.

Read the full article

orange arrow pointing right

12.16.2022

Oxford team aims to detect lung cancer early via a simple blood test

The team from Oxford University Hospitals (OUH) NHS Foundation Trust, the Oxford Radcliffe Biobank and the local spin-out company Oxford Cancer Analytics (OXcan) will recruit 200 participants to identify cancer biomarkers - molecules such as proteins found in blood that are a sign of lung cancer.

Read more

orange arrow pointing right

10.20.2021

OXFO Elevate Success Story Snippets: OXcan

Ahead of the OXFO annual Demo Day in November, they look at some of the success stories of our past-cohort ventures and how the Elevate accelerator has played a pivotal role in their growth. This snippet focuses on Oxford Cancer Analytics (OXcan), which was one of their portfolio ventures in cohort 3 in 2020.

Read more

orange arrow pointing right

9.28.2021

Top funds and angels back ambitious startup Oxford Cancer Analytics to detect lung cancer early

Can we beat lung cancer? OXcan, can. Every day in the UK, around 130 people are diagnosed with lung cancer. If you’re diagnosed during its earliest stage, you have a 57% chance of living for more than five years. If you’re diagnosed during its latest stage, your chances of survival are reduced to just 3%. That’s why lung cancer is the deadliest cancer anyone can face. Fortunately, OXcan is striving to identify more cases, earlier.

Read more

orange arrow pointing right

9.28.2021

Meet the team on a mission to save millions of lives through tech-based early-stage cancer detection.

Peter Jianrui Liu and Andreas Halner are the Co-founders of Oxford Cancer Analytics (OxCAN), one of the portfolio ventures on cohort 3 of the OXFO L.E.V8 accelerator at the Oxford Foundry. OxCAN offers personalised platforms to detect cancer early through a blood test to enable targeted curative treatments. Peter (Jesus College) is a DPhil candidate in Clinical Medicine, and Andreas (St John's) is doing a DPhil in Clinical Medicine and Machine Learning. In 2019, the duo won the grand prize in the Oxford Foundry's All-Innovate student ideas competition, which returns this month.

Read more

orange arrow pointing right

Press contact

For press enquiries, interviews and requests to re-use content, please contact us

Dr. Peter Jianrui Liu

Dr. Peter Jianrui Liu

Chief Executive Officer

p.liu@oxcan.org